Angionetics Inc.
Quick facts
Phase 3 pipeline
- Ad5FGF-4 · Cardiovascular
Ad5FGF-4 is a gene therapy that delivers fibroblast growth factor 4 (FGF-4) via an adenovirus vector to promote angiogenesis and improve blood flow in ischemic tissues.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: